Latest Cardiology News

Page 4 of 6
CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.
Ada Torres
Ada Torres
30 Oct 2025
Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.
Ada Torres
Ada Torres
28 Oct 2025
Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.
Ada Torres
Ada Torres
22 Oct 2025
Imricor Medical Systems has completed the world’s first Pulsed Field Ablation procedure under real-time MRI guidance, marking a breakthrough in cardiac ablation technology. This pre-clinical success validates their Vision-MR platform’s adaptability and sets the stage for safer, radiation-free heart treatments.
Ada Torres
Ada Torres
20 Oct 2025
Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.
Ada Torres
Ada Torres
16 Oct 2025
Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.
Ada Torres
Ada Torres
10 Oct 2025
Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.
Ada Torres
Ada Torres
2 Oct 2025
Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.
Ada Torres
Ada Torres
29 Sept 2025
Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.
Ada Torres
Ada Torres
19 Sept 2025
EBR Systems has achieved a significant commercial milestone with its tenth US implant of the WiSE wireless cardiac pacing system, setting the stage for broader market adoption supported by new reimbursement schemes.
Ada Torres
Ada Torres
17 Sept 2025
Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.
Ada Torres
Ada Torres
29 Aug 2025
BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.
Ada Torres
Ada Torres
28 Aug 2025